Tags

Type your tag names separated by a space and hit enter

Therapeutic options in osteoporosis.
Acta Biomed 2010; 81 Suppl 1:55-65AB

Abstract

Osteoporosis is a major and global public health concern. This disorder is characterized by a compromised bone strength and increased susceptibility to fractures, with important health and socioeconomic consequences. Age remains a cardinal, independent determinant of fracture risk; hence, the prevalence of osteoporotic fractures is expected to rise as the proportion of older populations increases worldwide. The prevention of osteoporosis should begin early and continue all the way through life with measures that improve or maintain bone health including regular physical activity and a balanced diet, considering not only an adequate intake of calcium but also of other minerals, proteins, and food rich in antioxidants. Smoking and alcohol abuse should be avoided. In older persons, who are particularly at risk of fragility fractures, the prevention of falls and the maintenance of an adequate vitamin D status are essential. Assessment of fracture risk followed by proved effective nonpharmacological and pharmacological management is still low, even in patients who have sustained a fragility fracture. Nonpharmacologic strategies should always be implemented, but many patients also need pharmacologic intervention to achieve adequate fracture protection. It is clear today that although low bone mineral density (BMD) is an important determinant of bone fragility, it is not the only one, hence, drugs used in the treatment of osteoporosis must not only show to promote changes in BMD, but to reduce the incidence of fractures. Safety issues should be always considered in an individual basis. This article reviews the available nonpharmacologic and pharmacologic interventions -proved to be effective- that may be implemented to reduce the risk of osteoporotic fractures.

Authors+Show Affiliations

Geriatric Unit, Department of Clinical Medicine and Emergent Pathologies, University of Palermo, Italy.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20518192

Citation

Dominguez, Ligia J., et al. "Therapeutic Options in Osteoporosis." Acta Bio-medica : Atenei Parmensis, vol. 81 Suppl 1, 2010, pp. 55-65.
Dominguez LJ, Scalisi R, Barbagallo M. Therapeutic options in osteoporosis. Acta Biomed. 2010;81 Suppl 1:55-65.
Dominguez, L. J., Scalisi, R., & Barbagallo, M. (2010). Therapeutic options in osteoporosis. Acta Bio-medica : Atenei Parmensis, 81 Suppl 1, pp. 55-65.
Dominguez LJ, Scalisi R, Barbagallo M. Therapeutic Options in Osteoporosis. Acta Biomed. 2010;81 Suppl 1:55-65. PubMed PMID: 20518192.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic options in osteoporosis. AU - Dominguez,Ligia J, AU - Scalisi,Rosalinda, AU - Barbagallo,Mario, PY - 2010/6/4/entrez PY - 2010/6/4/pubmed PY - 2010/7/23/medline SP - 55 EP - 65 JF - Acta bio-medica : Atenei Parmensis JO - Acta Biomed VL - 81 Suppl 1 N2 - Osteoporosis is a major and global public health concern. This disorder is characterized by a compromised bone strength and increased susceptibility to fractures, with important health and socioeconomic consequences. Age remains a cardinal, independent determinant of fracture risk; hence, the prevalence of osteoporotic fractures is expected to rise as the proportion of older populations increases worldwide. The prevention of osteoporosis should begin early and continue all the way through life with measures that improve or maintain bone health including regular physical activity and a balanced diet, considering not only an adequate intake of calcium but also of other minerals, proteins, and food rich in antioxidants. Smoking and alcohol abuse should be avoided. In older persons, who are particularly at risk of fragility fractures, the prevention of falls and the maintenance of an adequate vitamin D status are essential. Assessment of fracture risk followed by proved effective nonpharmacological and pharmacological management is still low, even in patients who have sustained a fragility fracture. Nonpharmacologic strategies should always be implemented, but many patients also need pharmacologic intervention to achieve adequate fracture protection. It is clear today that although low bone mineral density (BMD) is an important determinant of bone fragility, it is not the only one, hence, drugs used in the treatment of osteoporosis must not only show to promote changes in BMD, but to reduce the incidence of fractures. Safety issues should be always considered in an individual basis. This article reviews the available nonpharmacologic and pharmacologic interventions -proved to be effective- that may be implemented to reduce the risk of osteoporotic fractures. SN - 0392-4203 UR - https://www.unboundmedicine.com/medline/citation/20518192/Therapeutic_options_in_osteoporosis_ L2 - http://www.diseaseinfosearch.org/result/9059 DB - PRIME DP - Unbound Medicine ER -